Condition 1: Measles. Condition 2: Mumps. Condition 3: Rubella. Measles Mumps Rubella
Conditions
Interventions
we will inject 0/5 cc MMR vaccine with new mumps component (RS12).
Prevention
we will inject 0/5 cc MMR vaccine with new mumps component (RS12)
Sponsors
Razi Vaccine and Serum Research Institute
Eligibility
Sex/Gender
All
Age
18 Years to 49 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Negative history of any contact with patients infected by Measles, Rubella or Mumps viruses during the last two months; Not being under Immunocompromising treatment; Giving Informed Consent; Not being Pregnant and no plan for pregnancy within the next three months; Negative history of Autoimmune disorders; Not being under Radiotherapy; Negative history of any Chronic diseases. Exclusion Criteria: Positive history of Immunodeficiency; Positive history of Congenital disorders; Positive history of Genetic disease;Positive history of Liver disease; Positive history of Kidney disease;Temperature > 38.0 °C at the time of the first visit; Presence of an Acute Febrile disease at the time of the fist visit; Positive history of blood transfusion during the last three months; Positive history of receiving intramascular immunogluboline during the last three months; Positive history of Hypersensitivity to Vaccine; Positive history of severe adverse effect after previous MMR Vaccine injection; Positive history of active tuberculosis; Positive history of egg hypersensitivity; Positive history of thrombocytopenia.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urea. Timepoint: Before vaccination and two weeks after vaccination. Method of measurement: Autoanalyzer- Biochemical reagent ( mg/dl).;Blood cell count and differential count of white blood cell. Timepoint: Before vaccination and two weeks after vaccination. Method of measurement: cell counter.;Creatinin. Timepoint: Before vaccination and two weeks after vaccination. Method of measurement: Autoanalyzer- Biochemical reagent ( mg/dl).;Liver enzymes. Timepoint: Before vaccination and two weeks after vaccination. Method of measurement: Autoanalyzer- Biochemical reagent ( IU/ml).;Anaphylaxy. Timepoint: Within One hour after vaccination. Method of measurement: Assessed by the physician.;Allergic reaction. Timepoint: Within one hour after vaccination. Method of measurement: Assessed by the physician.;Thrombocytopenia. Timepoint: Within 6 weeks after vaccination. Method of measurement: Cell counter.;Fever. Timepoint: Within 6 weeks after vaccination. Method of measurement: Documented and assessed by the physician.;Pain of the injection site. Timepoint: Within 6 weeks after vaccination. Method of measurement: Documented and assessed by the physician.;Swelling of the injection site. Timepoint: Within 6 weeks after vaccination. Method of measurement: Documented and assessed by the physician.;Redness of the injection site. Timepoint: Within 6 weeks after vaccination. Method of measurement: Documented and assessed by the physician.;Severe headache. Timepoint: Within 6 weeks after vaccination. Method of measurement: Documented and assessed by the physician. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeedeh Forghani
Razi Vaccine and Serum Research Institute
Outcome results
None listed